Incyte (INCY) Common Equity (2010 - 2026)
Incyte posted quarterly Common Equity of $5.6 billion for Q1 2026, up 53.31% year-on-year from $3.7 billion in Q1 2025, and up 8.81% on a QoQ basis from $5.2 billion in Q4 2025.
Incyte (INCY) has 17 years of Common Equity data on file, last reported at $5.6 billion in Q1 2026.
- For the quarter ending Q1 2026, Common Equity rose 53.31% year-over-year to $5.6 billion; the trailing twelve-month figure through Mar 2026 stood at $5.6 billion (up 53.31% YoY), and the FY2025 full-year result was $5.2 billion, up 49.89% from the prior year.
- Common Equity for Q1 2026 stood at $5.6 billion, up from $5.2 billion in the prior quarter.
- Across five years, Common Equity topped out at $5.6 billion in Q1 2026 and bottomed at $3.0 billion in Q2 2024.
- The 5-year median for Common Equity is $4.4 billion (2022), against an average of $4.4 billion.
- The widest annual swing landed in 2024, when Common Equity plunged 36.78%; it then surged 53.31% in 2026.
- A 5-year view of Common Equity shows it stood at $4.4 billion in 2022, then gained by 18.76% to $5.2 billion in 2023, then plunged by 33.57% to $3.4 billion in 2024, then soared by 49.89% to $5.2 billion in 2025, then grew by 8.81% to $5.6 billion in 2026.
- The last three Common Equity figures came in at $5.6 billion (Q1 2026), $5.2 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 5.62 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.62 Bn |
| Dec 31, 2025 | 5.17 Bn |
| Sep 30, 2025 | 4.65 Bn |
| Jun 30, 2025 | 4.17 Bn |
| Mar 31, 2025 | 3.67 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 3.17 Bn |
| Jun 30, 2024 | 3.00 Bn |
| Mar 31, 2024 | 5.39 Bn |
| Dec 31, 2023 | 5.19 Bn |
| Sep 30, 2023 | 4.93 Bn |
| Jun 30, 2023 | 4.74 Bn |
| Mar 31, 2023 | 4.46 Bn |
| Dec 31, 2022 | 4.37 Bn |
| Sep 30, 2022 | 4.23 Bn |
| Jun 30, 2022 | 4.09 Bn |
| Mar 31, 2022 | 3.86 Bn |
| Dec 31, 2021 | 3.77 Bn |
| Sep 30, 2021 | 3.15 Bn |
| Jun 30, 2021 | 2.94 Bn |
| Mar 31, 2021 | 2.73 Bn |
| Dec 31, 2020 | 2.61 Bn |
| Sep 30, 2020 | 2.39 Bn |
| Jun 30, 2020 | 2.34 Bn |
| Mar 31, 2020 | 1.94 Bn |
| Dec 31, 2019 | 2.60 Bn |
| Sep 30, 2019 | 2.42 Bn |
| Jun 30, 2019 | 2.25 Bn |
| Mar 31, 2019 | 2.09 Bn |
| Dec 31, 2018 | 1.93 Bn |
| Sep 30, 2018 | 1.80 Bn |
| Jun 30, 2018 | 1.73 Bn |
| Mar 31, 2018 | 1.63 Bn |
| Dec 31, 2017 | 1.63 Bn |
| Sep 30, 2017 | 1.76 Bn |
| Jun 30, 2017 | 1.03 Bn |
| Mar 31, 2017 | 965.93 Mn |
| Dec 31, 2016 | 419.47 Mn |
| Sep 30, 2016 | 369.99 Mn |
| Jun 30, 2016 | 297.06 Mn |
| Mar 31, 2016 | 227.75 Mn |
| Dec 31, 2015 | 171.16 Mn |
| Sep 30, 2015 | 88.74 Mn |
| Jun 30, 2015 | 55.17 Mn |
| Mar 31, 2015 | -41.41 Mn |
| Dec 31, 2014 | -81.63 Mn |
| Sep 30, 2014 | -89.59 Mn |
| Jun 30, 2014 | -171.00 Mn |
| Mar 31, 2014 | -162.42 Mn |
| Dec 31, 2013 | -193.11 Mn |
| Sep 30, 2013 | 28.79 Mn |
| Jun 30, 2013 | -27.79 Mn |
| Mar 31, 2013 | -163.53 Mn |
| Dec 31, 2012 | -174.96 Mn |
| Sep 30, 2012 | -219.95 Mn |
| Jun 30, 2012 | -217.19 Mn |
| Mar 31, 2012 | -248.86 Mn |
| Dec 31, 2011 | -227.08 Mn |
| Sep 30, 2011 | -181.02 Mn |
| Jun 30, 2011 | -136.28 Mn |
| Mar 31, 2011 | -103.98 Mn |
| Dec 31, 2010 | -88.64 Mn |